Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MGH cancer specialists propose new approval track for targeted drugs

12.08.2004


’Selective approval’ would require follow up studies to identify most appropriate patients

One of the most promising new strategies for cancer treatment is the development of drugs that directly target molecular abnormalities that lead to the growth of tumors. Several such drugs have received Food and Drug Administration (FDA) approval in recent years, but some have been controversial because the data on which they were approved did not clearly define which patients will most benefit from the new medications.

Writing in the July 29 New England Journal of Medicine, two specialists from the Massachusetts General Hospital (MGH) Cancer Center propose an expansion of the FDA’s "fast-track" programs for drug approval. In their "Sounding Board" piece, Thomas Roberts Jr., MD, and Bruce Chabner, MD, call on the FDA to require pharmaceutical companies to carry out studies identifying the patients most likely to respond to a targeted-therapy drug, as a condition of the drug’s approval.



"Throughout the 1980s members of the AIDS community were incredibly effective in influencing the FDA to allow easier access to antiretroviral drugs," says Roberts. "The resulting fast-track programs allow more rapid review and approval of drugs to treat many serious conditions that have no effective treatment."

While fast-track approval has opened up important therapeutic options for many patients, Roberts adds, without the detailed data provided by fully controlled clinical trials, physicians may not have information that clarifies who should or should not receive the medications. "With a new drug that costs $15,000, you don’t want to shoot in the dark and just hope this patient will be the one in ten who will benefit. And since choosing one of these drugs means you may have to exclude a different one, you don’t want to waste time with an agent that won’t help that patient."

He and Chabner propose institution of a mechanism they call "selective approval," which could be piloted for cancer drugs and eventually used for medications treating other conditions. Under selective approval, targeted drugs could receive fast-track approval based on consistent antitumor responses in early clinical trials, provided that the sponsoring pharmaceutical company has begun studies designed to identify the patients most likely to respond to the therapy. The approval would be reviewed annually and could be withdrawn if the clarifying research were not completed. On the other hand, completion of controlled clinical trials would convert the approval to full status.

"The advent of targeted cancer reatments has brought great enthusiasm for what some refer to as personalized medicine," says Roberts, "but there has also been disappointment that so few of these individualized approaches have become available to patients. One of the FDA’s fast-track programs, called accelerated approval, which looks at surrogates for clinical benefit [biomarkers] instead of waiting for definitive evidence of clinical benefit [e.g. improvement in survival time], is an important first step that we think should go further. The next step will require investing in the studies that will help us, as clinicians, better target therapies to the patients that will benefit the most."

Roberts is an instructor in Medicine at Harvard Medical School, and Chabner, clinical director of the MGH Cancer Center, is a professor of Medicine. Their report is supported by grants from the National Cancer Institute and the PhRMA Foundation.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>